Related Experiment Video
Updated: Jul 27, 2026
In Vivo Modeling of the Morbid Human Genome using Danio rerio
Published on: August 24, 2013
Miller Fisher Syndrome: A Case Report Highlighting Heterogeneity of Clinical Features and Focused Differential
Ilya V Yepishin1, Randall Z Allison1, David A Kaminskas1
1Family Medicine Residency Program, John A. Burns School of Medicine, University of Hawai'i, Honolulu, HI (IVY).
Abstract:
Miller Fisher Syndrome (MFS) is a rare variant of Guillain-Barré Syndrome (GBS) that has a geographically variable incidence. It is largely a clinical diagnosis based on the cardinal clinical features of ataxia, areflexia, and opthalmoplegia, however, other neurological signs and symptoms may also be present. Serological confirmation with the anti-GQ1b antibody is available and allows for greater diagnostic certainty in the face of confounding symptoms. A self-limiting course is typical of MFS. The following case report is that of a patient who presented with generalized weakness, somatic pain, inability to walk, and diplopia following an upper respiratory illness. The patient exhibited the classic triad of ataxia, areflexia, and opthalmoplegia characteristic of MFS, but also had less typical signs and symptoms making for a more challenging diagnostic workup. Our suspected diagnosis of MFS was serologically confirmed with positive anti-GQ1b antibody titer and the patient was successfully treated with Intravenous immune globulin (IVIG).
Insights
Miller Fisher Syndrome (MFS), a rare Guillain-Barré Syndrome variant, presents with ataxia, areflexia, and ophthalmoplegia. This case report details a patient successfully treated with Intravenous immune globulin (IVIG) after serological confirmation.
Area of Science:
- Neurology
- Immunology
Background:
- Miller Fisher Syndrome (MFS) is a rare variant of Guillain-Barré Syndrome (GBS), characterized by a geographically variable incidence.
- Diagnosis is primarily clinical, relying on ataxia, areflexia, and ophthalmoplegia, though atypical presentations occur.
- Anti-GQ1b antibody testing offers serological confirmation, enhancing diagnostic certainty.
Observation:
- A case report details a patient presenting with generalized weakness, pain, gait disturbance, and diplopia post-upper respiratory infection.
- The patient exhibited the classic MFS triad but also presented with less typical neurological signs and symptoms.
- Diagnostic challenges arose due to the combination of classic and atypical MFS manifestations.
Findings:
- The patient's suspected MFS diagnosis was confirmed through serological testing, revealing a positive anti-GQ1b antibody titer.
- Treatment with Intravenous immune globulin (IVIG) resulted in a successful clinical outcome.
- The self-limiting nature typical of MFS was observed, alongside effective therapeutic intervention.
Implications:
- This case highlights the importance of serological confirmation in MFS diagnosis, especially with atypical symptoms.
- Intravenous immune globulin (IVIG) demonstrates efficacy in treating Miller Fisher Syndrome.
- Understanding MFS variants and diagnostic nuances is crucial for timely and accurate patient management.
More Related Videos
Related Concept Videos
01:23Mitral Stenosis II: Clinical features and Diagnostic Tests
01:19Autism Spectrum Disorder
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.